Lack of myeloid cell infiltration as an acquired resistance strategy to immunotherapy.
active
immunotherapy
tumor escape
tumor microenvironment
vaccination
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
accepted:
06
08
2020
entrez:
3
9
2020
pubmed:
3
9
2020
medline:
15
10
2021
Statut:
ppublish
Résumé
Immunotherapy of cancer is successful but tumor regression often is incomplete and followed by escape. Understanding the mechanisms underlying this acquired resistance will aid the development of more effective treatments. We exploited a mouse model where tumor-specific therapeutic vaccination results in tumor regression, followed by local recurrence and resistance. In depth studies on systemic, local and tumor intrinsic changes were performed with flow and mass cytometry, immunohistochemistry, transcriptomics and several perturbation studies with inhibitors or agonistic antibodies in mice. Main findings were recapitulated in vaccinated patients. Full tumor regression and cure of tumor-bearing mice is dependent on the magnitude of the vaccine-induced T-cell response. Recurrence of tumors did not involve classical immune escape mechanisms, such as antigen-presentation alterations, immune checkpoint expression, resistance to killing or local immune suppression. However, the recurrent tumors displayed a changed transcriptome with alterations in p53, tumor necrosis factor-α and transforming growth factor-β signaling pathways and they became immunologically cold. Remarkably, ex vivo cell-sorted recurrent tumors, directly reinjected in naïve hosts retained their resistance to vaccination despite a strong infiltration with tumor-specific CD8 An immunotherapy-induced disability of tumor cells to attract innate myeloid effector cells formed a major mechanism underlying immune escape and acquired resistance. These data not only stresses the importance of myeloid effector cells during immunotherapy but also demands for new studies to harness their tumoricidal activities.
Sections du résumé
BACKGROUND
Immunotherapy of cancer is successful but tumor regression often is incomplete and followed by escape. Understanding the mechanisms underlying this acquired resistance will aid the development of more effective treatments.
METHODS
We exploited a mouse model where tumor-specific therapeutic vaccination results in tumor regression, followed by local recurrence and resistance. In depth studies on systemic, local and tumor intrinsic changes were performed with flow and mass cytometry, immunohistochemistry, transcriptomics and several perturbation studies with inhibitors or agonistic antibodies in mice. Main findings were recapitulated in vaccinated patients.
RESULTS
Full tumor regression and cure of tumor-bearing mice is dependent on the magnitude of the vaccine-induced T-cell response. Recurrence of tumors did not involve classical immune escape mechanisms, such as antigen-presentation alterations, immune checkpoint expression, resistance to killing or local immune suppression. However, the recurrent tumors displayed a changed transcriptome with alterations in p53, tumor necrosis factor-α and transforming growth factor-β signaling pathways and they became immunologically cold. Remarkably, ex vivo cell-sorted recurrent tumors, directly reinjected in naïve hosts retained their resistance to vaccination despite a strong infiltration with tumor-specific CD8
CONCLUSION
An immunotherapy-induced disability of tumor cells to attract innate myeloid effector cells formed a major mechanism underlying immune escape and acquired resistance. These data not only stresses the importance of myeloid effector cells during immunotherapy but also demands for new studies to harness their tumoricidal activities.
Identifiants
pubmed: 32873723
pii: jitc-2020-001326
doi: 10.1136/jitc-2020-001326
pmc: PMC7467529
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Science. 2011 Mar 25;331(6024):1565-70
pubmed: 21436444
Br J Cancer. 2007 Aug 6;97(3):398-404
pubmed: 17637685
Nature. 2012 Feb 08;482(7385):400-4
pubmed: 22318521
Nat Rev Clin Oncol. 2017 Dec;14(12):717-734
pubmed: 28741618
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
PLoS One. 2016 Apr 19;11(4):e0153550
pubmed: 27092773
Methods Mol Biol. 2016;1418:283-334
pubmed: 27008021
Nat Immunol. 2001 Mar;2(3):261-8
pubmed: 11224527
Cell. 2017 Feb 9;168(4):707-723
pubmed: 28187290
Nature. 2018 Feb 22;554(7693):544-548
pubmed: 29443960
Nat Rev Cancer. 2011 Dec 08;12(1):58-67
pubmed: 22158022
Nature. 2018 May;557(7706):575-579
pubmed: 29769722
Cancer Sci. 2009 Apr;100(4):663-70
pubmed: 19462508
J Immunol. 2002 Jul 1;169(1):350-8
pubmed: 12077264
Front Cell Infect Microbiol. 2018 Jul 19;8:247
pubmed: 30073152
Oncogene. 2011 Mar 10;30(10):1147-58
pubmed: 21151176
Nature. 2011 Nov 09;479(7374):547-51
pubmed: 22080947
Lancet Oncol. 2015 Apr;16(4):375-84
pubmed: 25795410
Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12293-7
pubmed: 12218188
Annu Rev Immunol. 2010;28:57-78
pubmed: 20307208
Cancer Immunol Res. 2017 Aug;5(8):642-653
pubmed: 28637878
Cancer Immunol Immunother. 2017 Jun;66(6):705-716
pubmed: 28243692
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Nature. 2018 Feb 22;554(7693):538-543
pubmed: 29443964
Theranostics. 2018 Nov 29;8(22):6307-6321
pubmed: 30613299
Nat Commun. 2017 Nov 23;8(1):1740
pubmed: 29170529
Curr Opin Immunol. 2014 Apr;27:16-25
pubmed: 24531241
PLoS One. 2015 May 11;10(5):e0126765
pubmed: 25962156
Nat Rev Mol Cell Biol. 2014 Mar;15(3):178-96
pubmed: 24556840
Clin Cancer Res. 2019 Jan 1;25(1):240-252
pubmed: 30224343
Lancet Oncol. 2017 May;18(5):611-622
pubmed: 28359784
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
J Exp Med. 2019 Oct 7;216(10):2394-2411
pubmed: 31375534
Nat Rev Cancer. 2016 Apr;16(4):219-33
pubmed: 26965076
Immunobiology. 2018 Jan;223(1):101-111
pubmed: 29032836
JAMA Oncol. 2019 Jan 1;5(1):67-73
pubmed: 30267032
Clin Cancer Res. 2015 Feb 15;21(4):781-94
pubmed: 25501579
Bioinformatics. 2017 Feb 1;33(3):414-424
pubmed: 27694195
Oncotarget. 2015 Sep 29;6(29):27832-46
pubmed: 26337837
Nature. 2011 Dec 21;480(7378):480-9
pubmed: 22193102
Cancer Res. 2016 Oct 15;76(20):6017-6029
pubmed: 27569212
Int J Cancer. 2013 Dec 15;133(12):2884-94
pubmed: 23740735
Cell. 2018 Dec 13;175(7):1744-1755.e15
pubmed: 30503208
Sci Transl Med. 2020 Mar 18;12(535):
pubmed: 32188726
Lancet Oncol. 2018 Nov;19(11):1480-1492
pubmed: 30361170
Cancer Immunol Res. 2015 Sep;3(9):1042-51
pubmed: 25888578
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32169871
Cancer Cell. 2011 Jan 18;19(1):72-85
pubmed: 21251614
Cancer Res. 1996 Jan 1;56(1):21-6
pubmed: 8548765
Sci Signal. 2014 Sep 23;7(344):re8
pubmed: 25249658